JPS6320208B2 - - Google Patents
Info
- Publication number
- JPS6320208B2 JPS6320208B2 JP54108648A JP10864879A JPS6320208B2 JP S6320208 B2 JPS6320208 B2 JP S6320208B2 JP 54108648 A JP54108648 A JP 54108648A JP 10864879 A JP10864879 A JP 10864879A JP S6320208 B2 JPS6320208 B2 JP S6320208B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- polyurethane film
- patch
- support
- undercoat layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】
本発明は伸縮性を有する透明貼付薬の製造法に
関するものであつて、その目的とするところは支
持体としてポリウレタンフイルムを使用すること
により、織布又は不織布を支持体とした従来の貼
付薬の欠点を改良することにある。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing a stretchable transparent adhesive patch, and its purpose is to use a woven or nonwoven fabric as a support by using a polyurethane film as a support. The aim is to improve the shortcomings of conventional patch drugs.
ハツカゴム膏の名で呼ばれる従来の貼付薬は、
支持体としてスフモス、ネル、フラノなどの織布
又は不織布を使用し、この支持体上に生ゴム、亜
鉛華、樹脂、老化防止剤などの混練物を塗布して
下引き層を設け、その下引き層上に軟化剤、粘着
性付与樹脂、充填剤及び膏体主薬を含有する均一
混練物を展延する方法で製造されている。そし
て、この場合の軟化剤としてはポリブテン、プロ
セスオイル等が、粘着性付与樹脂としてはポリテ
ルペン樹脂、直鎖炭化水素樹脂、水素添加ロジン
エステルなどが、充填剤としては、亜鉛華乃至二
酸化チタンなどがそれぞれ使用され、また膏体主
薬としてはサリチル酸メチル、サリチル酸グリコ
ール、カンフル、l―メントール、トウガラシ
(エキス)、キヤプサイシン、ノニル酸ワニリルア
ミド、副腎皮質ホルモン及び皮膚保護薬などが通
常2種以上混合して使用されている。 The conventional patch medicine called Hatsuka gum plaster is
A woven or non-woven fabric such as sfumos, flannel, or flannel is used as a support, and a subbing layer is provided by coating a kneaded material such as crude rubber, zinc white, resin, or anti-aging agent on this support. It is manufactured by spreading a homogeneous kneaded material containing a softener, a tackifying resin, a filler, and a base ingredient on a layer. In this case, the softening agent is polybutene, process oil, etc., the tackifying resin is polyterpene resin, linear hydrocarbon resin, hydrogenated rosin ester, etc., and the filler is zinc oxide, titanium dioxide, etc. Each is used individually, and the main ingredients for the plaster include methyl salicylate, glycol salicylate, camphor, l-menthol, capsicum (extract), capsaicin, nonylic acid vanillylamide, adrenal corticosteroids, and skin protectants, which are usually used as a mixture of two or more. has been done.
然るに上記の如き従来の貼付薬は、その支持体
が不透明であるため、患部に貼付すれば貼付した
ことが目立つうえ、縦横への伸縮特性が不充分で
あるため、皮膚の動きに順応し得ない弊害があつ
た。 However, since the support of the conventional patch medicines mentioned above is opaque, it is noticeable when applied to the affected area, and the ability to stretch vertically and horizontally is insufficient, making it difficult to adapt to the movement of the skin. There were some negative effects.
本発明は従来の織布又は不織布に代えてポリウ
レタンフイルムを支持体として使用することによ
り、従来の貼付薬に指摘される上記の欠点を一挙
に解消せんとするものである。 The present invention uses a polyurethane film as a support in place of conventional woven or nonwoven fabrics, thereby attempting to eliminate the above-mentioned drawbacks of conventional patch drugs at once.
而して本発明に係る透明貼付薬の製造法は、40
〜90重量%の生ゴムと、60〜10重量%のトリイソ
シアネートからなる組成物の有機溶剤溶液を、ポ
リウレタンフイルム上に塗布して乾燥することに
より下引き層を形成せしめ、しかる後この下引き
層上に生ゴムと軟化剤と粘着性付与樹脂と膏体主
薬を含有する混練物を塗布展延することからな
る。 Therefore, the method for manufacturing the transparent patch according to the present invention is as follows:
An organic solvent solution of a composition consisting of ~90% by weight of raw rubber and 60-10% by weight of triisocyanate is applied onto a polyurethane film and dried to form an undercoat layer. It consists of applying and spreading a kneaded material containing raw rubber, a softener, a tackifying resin, and a base ingredient for the paste.
伸縮性を有する透明な貼付薬の製造を目論む場
合、その支持体には従来の織布乃至は不織布に代
えて透明で伸縮性を有するプラスチツクフイルム
を使用することは当然であるが、貼付薬の性質上
支持体は通気性を備えていなければならない。そ
れ故本発明では可塑剤が含まれず、しかも温度変
化によつて柔軟性が殆ど変化しないポリウレタン
フイルムを支持体として使用する。しかし、ポリ
ウレタンフイルムとても膏体主薬を配合した混練
物を直接塗布展延したのでは、両者間の接着力が
不充分であるため、満足な貼付薬を得ることがで
きない。 When aiming to produce a stretchable transparent patch, it is natural to use a transparent and stretchable plastic film as the support instead of conventional woven or non-woven fabric. By nature, the support must be breathable. Therefore, in the present invention, a polyurethane film that does not contain a plasticizer and whose flexibility hardly changes due to temperature changes is used as a support. However, if a kneaded product containing a paste base ingredient is directly applied and spread on a polyurethane film, the adhesion between the two is insufficient, making it impossible to obtain a satisfactory patch.
而して本発明によれば、支持体ポリウレタンフ
イルムには下引き層が形成される。下引き層は生
ゴム40〜90重量%、トリイソシアネート60〜10重
量%からなる組成物の有機溶剤溶液を、ポリウレ
タンフイルム上に塗布して乾燥することによつて
形成される。この場合の有機溶剤としては、ゴム
揮発油、n―ヘキサン、ベンゼンなどが使用可能
である。 According to the present invention, an undercoat layer is formed on the support polyurethane film. The undercoat layer is formed by applying an organic solvent solution of a composition consisting of 40 to 90% by weight of crude rubber and 60 to 10% by weight of triisocyanate onto a polyurethane film and drying it. As the organic solvent in this case, rubber volatile oil, n-hexane, benzene, etc. can be used.
こうしてポリウレタンフイルム上に下引き層が
形成されれば、その下引き層上には次いで膏体主
薬を含有する混練物が塗布展延されて、薬剤層が
形成される。この薬剤層形成用混練物には、本発
明の場合、軟化剤としてポリブテンが、粘着性付
与樹脂としてはポリテルペン樹脂(例:ys―レジ
ン)、直鎖炭化水素樹脂(例:エスコレツツ)、水
添ロジンエステル(例:エステルガム)などが、
膏体主薬としてはサリチル酸メチル、サリチル酸
グリコール、カンフル、l―メントール、トウガ
ラシ(エキス)、キヤプサイシン、ノニル酸ワニ
リルアミド、副腎皮質ホルモン乃至は皮膚保護薬
などが通常2種以上混合使用されるが、この他従
来当業界で使用されて来た薬剤層構成成分も従来
通りの配合量で使用可能である。 Once the undercoat layer is formed on the polyurethane film in this way, a kneaded material containing a paste base agent is then applied and spread on the undercoat layer to form a drug layer. In the case of the present invention, this kneaded material for forming a drug layer contains polybutene as a softener, polyterpene resin (e.g. ys-resin), linear hydrocarbon resin (e.g. Escorets) and hydrogenated resin as tackifying resins. Rosin esters (e.g. ester gum) etc.
The main ingredients for the plaster include methyl salicylate, glycol salicylate, camphor, l-menthol, capsicum (extract), capsaicin, nonylic acid vanillylamide, adrenal corticosteroids, or skin protective agents, which are usually used in combination. Drug layer constituents conventionally used in the art can also be used in conventional amounts.
進んで実施例を示す。 Examples will now be presented.
実施例
生ゴム40〜90重量%、トリイソシアネート60〜
10重量%の組成物4.0gをn―ヘキサン40mlに溶
解し、この溶液をポリウレタンフイルムに塗布し
て50〜60℃で乾燥後、熟成させて下引き層をポリ
ウレタンフイルム上に形成させた。次いでこの下
引き層上に膏体主薬を含む混練物を塗布展延して
伸縮性を有する透明貼付薬を得た。なお、貼付薬
表面にはセロハン、ポリエチレンフイルム、ポリ
プロピレンフイルム、剥離紙などのライナーを貼
り付けた。Examples Raw rubber 40~90% by weight, triisocyanate 60~
4.0 g of a 10% by weight composition was dissolved in 40 ml of n-hexane, and this solution was applied to a polyurethane film, dried at 50 to 60°C, and aged to form an undercoat layer on the polyurethane film. Next, a kneaded material containing a plaster base was applied and spread on the undercoat layer to obtain a stretchable transparent patch. A liner such as cellophane, polyethylene film, polypropylene film, or release paper was attached to the surface of the patch.
こうして得た各貼付薬を80℃で180時間以上ギ
ヤオープンで虐待してみたが、薬効その他に何等
の異常も認めなかつた。 Each of the patch medicines obtained in this way was subjected to abuse at 80°C for more than 180 hours with the gear open, but no abnormality was observed in terms of efficacy or otherwise.
Claims (1)
リイソシアネートからなる組成物の有機溶剤溶液
を、ポリウレタンフイルム上に塗布して乾燥する
ことにより下引き層を形成せしめ、しかる後この
下引き層上に生ゴムと軟化剤と粘着性付与樹脂と
膏体主薬を含有する混練物を塗布展延することか
らなる伸縮性を有する透明貼付薬の製法。1 An organic solvent solution of a composition consisting of 40 to 90% by weight of raw rubber and 60 to 10% by weight of triisocyanate is applied onto a polyurethane film and dried to form an undercoat layer. A method for manufacturing a transparent adhesive patch having elasticity, which comprises applying and spreading a kneaded material containing raw rubber, a softener, a tackifying resin, and a base agent on a pull layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10864879A JPS5632414A (en) | 1979-08-28 | 1979-08-28 | Preparation of stretchable clear sticking plaster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10864879A JPS5632414A (en) | 1979-08-28 | 1979-08-28 | Preparation of stretchable clear sticking plaster |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5632414A JPS5632414A (en) | 1981-04-01 |
| JPS6320208B2 true JPS6320208B2 (en) | 1988-04-26 |
Family
ID=14490126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10864879A Granted JPS5632414A (en) | 1979-08-28 | 1979-08-28 | Preparation of stretchable clear sticking plaster |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5632414A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01135505U (en) * | 1988-03-08 | 1989-09-18 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61167615A (en) * | 1985-01-18 | 1986-07-29 | Teisan Seiyaku Kk | Administration of drug |
| ES2336054T3 (en) | 1998-12-18 | 2010-04-07 | Alza Corporation | TRANSPARENT DEVICE FOR THE TRANSDERMIC ADMINISTRATION OF NICOTINE. |
| WO2009041301A1 (en) | 2007-09-27 | 2009-04-02 | Sumida Corporation | Composite magnetic device |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4867062U (en) * | 1971-12-04 | 1973-08-25 | ||
| JPS502979U (en) * | 1973-05-14 | 1975-01-13 |
-
1979
- 1979-08-28 JP JP10864879A patent/JPS5632414A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01135505U (en) * | 1988-03-08 | 1989-09-18 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5632414A (en) | 1981-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3007368C2 (en) | ||
| DE3843239C1 (en) | ||
| DE3111734C2 (en) | ||
| DE3743946C2 (en) | ||
| CN104136025B (en) | Adhesive | |
| DE69916492T3 (en) | PLASTER FOR THE TRANSDERMAL APPLICATION OF VOLATILE, LIQUID ACTIVE SUBSTANCES | |
| DD290582A5 (en) | METHOD FOR PRODUCING A TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF PHYSOSTIGMIN TO THE SKIN | |
| AU2004238119B2 (en) | External patch containing estrogen and/or progestogen | |
| JPH07138153A (en) | Percutaneous supply of effective medicine | |
| CN102245729B (en) | Self-adhesive matrix system comprising a styrene block copolymer | |
| CA2610414C (en) | Skin patch | |
| CA2335247C (en) | Method for manufacturing a laminate consisting of individual layers | |
| US20080233177A1 (en) | Fibre-Free Transdermal Therapeutic System and Method For Its Production | |
| DE2808717A1 (en) | MEDICAL AIDS AND MATERIALS SUITABLE FOR THEM | |
| CN1946429B (en) | Patch preparation | |
| JPH03127727A (en) | Pasting agent | |
| JP5243158B2 (en) | Patch and patch preparation | |
| JPS6320208B2 (en) | ||
| DE4403487C2 (en) | Pharmaceutical patches with UV-crosslinkable acrylate copolymers | |
| US2164360A (en) | Wound dressing | |
| JPS6340766B2 (en) | ||
| US6207183B1 (en) | Surface-stabilized pharmaceutical preparation for application on the skin | |
| JPS6258332B2 (en) | ||
| JPH05208907A (en) | Antiinflammatory and analgesic cataplasm | |
| JPH03112557A (en) | Application agent |